Testing a new treatment for methamphetamine addiction
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder
This study is testing a new treatment for people dealing with methamphetamine addiction, using a special molecule to see if it can help reduce cravings and improve thinking skills, and it's looking for both healthy volunteers and those with addiction to participate.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virogenomics Biodevelopment, INC. NIH-funded |
| Lab location | 1 site (Tigard, UNITED STATES) |
| Project ID | NIH-11011421 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for individuals struggling with methamphetamine addiction, focusing on a molecule called DRhQ that targets the CD74 receptor. The study aims to conduct phase I clinical trials to assess the safety of this treatment in both healthy volunteers and those diagnosed with methamphetamine use disorder. By utilizing animal models and human trials, the research seeks to understand how this treatment can reduce drug-seeking behavior and improve cognitive function affected by addiction. The ultimate goal is to provide a pharmacotherapeutic option for patients who currently have limited treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are struggling with methamphetamine use disorder.
Not a fit: Patients who are not addicted to methamphetamine or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new medication to help individuals overcome methamphetamine addiction and reduce relapse rates.
How similar studies have performed: While the approach of targeting immune factors in addiction is emerging, this specific treatment and its application in methamphetamine use disorder is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Tigard, UNITED STATES
- Virogenomics Biodevelopment, INC. — Tigard, United States (Active)
Researchers
- Principal investigator: Shirley, Renee Lynn — Virogenomics Biodevelopment, INC.
- Study coordinator: Shirley, Renee Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.